These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39282196)

  • 21. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature.
    Grabein B; Graninger W; Rodríguez Baño J; Dinh A; Liesenfeld DB
    Clin Microbiol Infect; 2017 Jun; 23(6):363-372. PubMed ID: 27956267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
    Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
    Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The management of multidrug-resistant Enterobacteriaceae.
    Bassetti M; Peghin M; Pecori D
    Curr Opin Infect Dis; 2016 Dec; 29(6):583-594. PubMed ID: 27584587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015.
    Castanheira M; Griffin MA; Deshpande LM; Mendes RE; Jones RN; Flamm RK
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5623-4. PubMed ID: 27401568
    [No Abstract]   [Full Text] [Related]  

  • 26. Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli.
    Guo Q; Tomich AD; McElheny CL; Cooper VS; Stoesser N; Wang M; Sluis-Cremer N; Doi Y
    J Antimicrob Chemother; 2016 Sep; 71(9):2460-5. PubMed ID: 27261267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance.
    Castañeda-García A; Blázquez J; Rodríguez-Rojas A
    Antibiotics (Basel); 2013 Apr; 2(2):217-36. PubMed ID: 27029300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.
    Vardakas KZ; Legakis NJ; Triarides N; Falagas ME
    Int J Antimicrob Agents; 2016 Apr; 47(4):269-85. PubMed ID: 27013000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosfomycin.
    Falagas ME; Vouloumanou EK; Samonis G; Vardakas KZ
    Clin Microbiol Rev; 2016 Apr; 29(2):321-47. PubMed ID: 26960938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of high-dose fosfomycin guided by NT-proBNP.
    Candel FJ; Matesanz M; Martín-Sánchez FJ; González Del Castillo JM
    Int J Cardiol; 2016 Apr; 209():131-2. PubMed ID: 26889596
    [No Abstract]   [Full Text] [Related]  

  • 31. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection.
    Tajiri H; Nishi J; Ushijima K; Shimizu T; Ishige T; Shimizu M; Tanaka H; Brooks S
    Int J Antimicrob Agents; 2015 Nov; 46(5):586-9. PubMed ID: 26391378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
    Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).
    Habib G; Lancellotti P; Antunes MJ; Bongiorni MG; Casalta JP; Del Zotti F; Dulgheru R; El Khoury G; Erba PA; Iung B; Miro JM; Mulder BJ; Plonska-Gosciniak E; Price S; Roos-Hesselink J; Snygg-Martin U; Thuny F; Tornos Mas P; Vilacosta I; Zamorano JL;
    Eur Heart J; 2015 Nov; 36(44):3075-3128. PubMed ID: 26320109
    [No Abstract]   [Full Text] [Related]  

  • 34. Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.
    Parker SL; Frantzeskaki F; Wallis SC; Diakaki C; Giamarellou H; Koulenti D; Karaiskos I; Lipman J; Dimopoulos G; Roberts JA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6471-6. PubMed ID: 26239990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
    VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI).
    Vidal E; Cervera C; Cordero E; Armiñanzas C; Carratalá J; Cisneros JM; Fariñas MC; López-Medrano F; Moreno A; Muñoz P; Origüen J; Sabé N; Valerio M; Torre-Cisneros J; ;
    Enferm Infecc Microbiol Clin; 2015 Dec; 33(10):679.e1-679.e21. PubMed ID: 25976754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibility of Aerococcus urinae isolates to antibiotics used for uncomplicated urinary tract infection.
    Hirzel C; Guilarte YN; Hirzberger L; Furrer H; Marschall J; Endimiani A
    J Infect; 2015 Sep; 71(3):395-7. PubMed ID: 25912613
    [No Abstract]   [Full Text] [Related]  

  • 39. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The changing epidemiology of bacteraemic osteoarticular infections in the early 21st century.
    Murillo O; Grau I; Lora-Tamayo J; Gomez-Junyent J; Ribera A; Tubau F; Ariza J; Pallares R
    Clin Microbiol Infect; 2015 Mar; 21(3):254.e1-8. PubMed ID: 25618436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.